Results 11 to 20 of about 19,471 (205)

Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias

Journal of Cardiovascular Development and Disease, 2022
The study investigates the prognostic role of treatment with carvedilol as compared to metoprolol in patients with ventricular tachyarrhythmias. A large retrospective registry was used including consecutive patients on beta-blocker (BB) treatment with ...
Tobias Schupp, Michael Behnes, Mohammad Abumayyaleh, Kathrin Weidner, Jonas Rusnak, Kambis Mashayekhi, Thomas Bertsch, Ibrahim Akin   +7 more
doaj   +2 more sources

Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation

International Journal of Nanomedicine, 2015
Dandan Liu,1 Hao Pan,2 Fengwei He,1 Xiaoyu Wang,3 Jinyu Li,3 Xinggang Yang,3 Weisan Pan31Department of Pharmaceutical Engineering, School of Biomedical and Chemical Engineering, Liaoning Institute of Science and Technology, Benxi, People’s Republic
Liu DD, Pan H, He FW, Wang XY, Li JY, Yang XG, Pan WS   +6 more
doaj   +1 more source

Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension [PDF]

Frontiers in Cardiovascular Medicine, 2018
Background: The therapeutic benefits of β-blockers are well established in left heart failure. The Pulmonary Arterial Hypertension Treatment with Carvedilol for Heart Failure [PAHTCH] study showed safety and possible benefit of carvedilol in pulmonary ...
Hoi I Cheong, Samar Farha, Margaret M. Park, James D. Thomas, Didem Saygin, Suzy A. A. Comhair, Jacqueline Sharp, Jacqueline Sharp, Kristin B. Highland, W. H. Wilson Tang, W. H. Wilson Tang, Serpil C. Erzurum, Serpil C. Erzurum   +12 more
doaj   +2 more sources

Carvedilol in the treatment of chronic heart failure: Lessons from The Carvedilol Or Metoprolol European Trial

Vascular Health and Risk Management, 2007
Britt Kveiborg, Atheline Major-Petersen, Buris Christiansen, Christian Torp-PedersenDepartment of Cardiology, Bispebjerg University Hospital, Copenhagen, DenmarkAbstract: Beta-blockers have been shown to improve survival in patients with chronic heart ...
Britt Kveiborg, Atheline Major-Petersen, Buris Christiansen, Christian Torp-Pedersen   +3 more
doaj   +1 more source

Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans : lost in translation [PDF]

, 2013
We greatly appreciate the comments offered by Drs Rolle, Takematsu, and Hoffman and the opportunity to put our work into a wider perspective. We share the view that our work does not reflect the clinical situation but rather provides a proof of mechanism
Liechti, M. E., Schmid, Y., Rickli, A., Hysek, C. M., Yasmin Schmid, Anna Rickli, Cédric M Hysek, Matthias E Liechti   +7 more
core   +1 more source

The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist [PDF]

, 2013
Nebivolol, a third generation β-adrenoceptor (β-AR) antagonist (β-blocker), causes vasodilation by inducing nitric oxide (NO) production. The mechanism via which nebivolol induces NO production remains unknown, resulting in the genesis of much of the ...
Jackson, Edwin K., Blessing, CP, Tammy Liu, Liu, Tammy, Liu, T, Christopher P Blessing, Jackson Edwin K., Liu Tammy, Gul, R, Pulakat, Lakshmi, Pulakat, L, Murat Bastepe, Blessing, Christopher P., Edwin K Jackson, Catherine E Erickson, Rukhsana Gul, Bastepe Murat, Lakshmi Pulakat, Andresen Bradley T., Nguyen, J, Pulakat Lakshmi, Gul, Rukhsana, Andresen, Bradley T., Erickson, CE, Blessing Christopher P., Holowka, David, Nguyen Jenny, Bastepe, Murat, Jackson, EK, Andresen, BT, Gul Rukhsana, Jenny Nguyen, Erickson Catherine E., Bastepe, M, Erickson, Catherine E., Nguyen, Jenny, Bradley T Andresen   +36 more
core   +2 more sources

Drug delivery of carvedilol (cardiovascular drug) using phosphorene as a drug carrier: a DFT study

Journal of Taibah University for Science, 2022
2D nanomaterial phosphorene is a chemistically stable, biocompatible, and biodegradable drug delivery platform. This study investigates the drug loading efficiency of phosphorene for the cardiovascular drug carvedilol using density-functional theory (DFT)
Javeria Rafique, Qaba Qusain Afzal, Mehvish Perveen, Javed Iqbal, Mohammed Salim Akhter, Sidra Nazir, M. S. Al-Buriahi, Sultan Alomairy, Z. A. Alrowaili   +8 more
doaj   +1 more source

COMPARATIVE CONTROLLED STUDY OF ANTIHYPERTENSIVE EFFICACY AND SAFETY OF CARVEDILOL IN PATIENTS WITH HYPERTENSION AND OBESITY OR DIABETES 2 TYPE (BASED ON RESULTS OF MULTICENTER TRIAL ACCORD)

Рациональная фармакотерапия в кардиологии, 2016
Aim. To study efficacy and safety of beta-blocker with vasodilating properties carvedilol (Acridilole, Akrihin, Russia) as a part of the combined therapy of patients with arterial hypertension (HT) and diabetes mellitus 2 type (DM2) and/or obesity ...
Yu. V. Yu.V. Lukina, S. Yu. Martsevich, A. D. Deev, S. A. Shalnova   +3 more
doaj   +3 more sources

COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL

Рациональная фармакотерапия в кардиологии, 2016
Aim. To compare two therapies based on carvedilol or metoprolol in hypertensive patients with overweight and obesity.Material and methods. 320 patients with arterial hypertension (1-2 degree) were involved in the study.
S. Y. Martsevich, N. P. Kutishenko, E. V. Shilova, A. D. Deev, S. A. Shalnova, R. G. Oganov, I. A. Veliganina, E. G. Volkova, Yu. E. Voskanjan, L. I. Gapon, P Ya. Dovgalevskij, V. Ya. Ermolina, E. M. Idrisova, N. N. Ilov, A. R. Kiselev, S. Yu. Levashov, V. A. Nevzorova, G. I. Nechaeva, T. N. Panova, I. I. Reznik, V. V. Skibickij, L. A. Sokolova, V. P. Terentev, N. V. Hailo, A. V. Shabalin, T. V. Shnjukova, V. V. Yakusevich   +26 more
doaj   +3 more sources

In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells

Saudi Pharmaceutical Journal, 2023
Melanoma is an aggressive skin cancer. Increasing evidence has shown the role of β-adrenergic receptors in the pathogenesis of melanoma. Carvedilol is a widely used non-selective β-AR antagonist with potential anticancer activity.
Joanna Wawszczyk, Radosław Wolan, Sławomir Smolik, Małgorzata Kapral   +3 more
doaj   +1 more source